by Adam | Mar 4, 2020 | News
PROVIDENCE, R.I., Mar. 4, 2020 – EpiVax Inc., a Rhode Island company, announces a collaboration to develop a novel coronavirus SARS-CoV-2 (COVID-19) vaccine with University of Georgia (UGA, Athens GA) vaccine expert Ted Ross (Director, Center for Vaccines and...
by Annie De Groot | Nov 25, 2019 | Events, News
The annual World Vaccine and Immunotherapy Congress west coast meetings will be held on December 2-5, 2019 at the San Francisco Airport Marriott Waterfront Hotel Dr. Lenny Moise, the Director of Vaccine Research at EpiVax will be in attendance. His talk:...
by Adam | Nov 6, 2019 | News
Providence, November 6th 2019 EpiVax announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports EpiVax, Inc (“EpiVax”), a pioneer in immunoinformatics innovation, announces the publication of “Therapeutic administration of...
by Adam | Oct 23, 2019 | News
Announced today, Chugai Pharmaceutical Co., Ltd. (“Chugai”), a member of the Roche Group, will extend the company’s licensed access to the Immunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc....
by Annie De Groot | Aug 19, 2019 | Events
Were you unable to meet the EpiVax team at our last event? No worries! Below is a list of where we will present throughout the year: January 23: Babraham Immunogenicity Seminar (Cambridge, United Kingdom) Hosted by: IONTAS and EpiVax, Inc. Title: Evolution of In...
